Tag: Epidiolex

While cannabidiol (CBD) products derived from hemp became federally legal in 2018, only one pharmaceutical-grade CBD medication has received FDA approval. This critical distinction explains when and why a doctor would ever prescribe CBD, clarifying the difference between regulated medication and consumer wellness products.

Clinical trials have shown that a purified CBD extract can significantly reduce seizure frequency in certain severe forms of epilepsy. For this reason, many patients wonder **how much CBD to take for seizures**, but proper use requires understanding the crucial difference between a prescription product and unregulated CBD oil.

Epidiolex, the first FDA-approved prescription CBD medicine, is a highly purified form of cannabidiol, not a percentage-based product like many over-the-counter alternatives. Instead of a percentage, EPIDIOLEX contains a specific, standardized concentration of 100 milligrams of CBD per milliliter (mg/mL). This pharmaceutical-grade purity is a key distinction from unregulated commercial CBD oils.

As of late 2025, there is currently no therapeutically equivalent generic version of the prescription medication Epidiolex available in the United States. This means patients must rely on the branded product, which is the only FDA-approved cannabidiol for treating specific seizure disorders.

Initially launched with an annual wholesale price of approximately $32,500, the cost of Epidiolex can be a significant barrier for many patients. The complex reasons behind **why is Epidiolex so expensive** involve a multifaceted journey from lab to market, driven by stringent regulation and economic factors.

The U.S. Food and Drug Administration (FDA) first approved a prescription cannabidiol oral solution (Epidiolex®) in 2018 for treating specific, severe forms of epilepsy. This medication has since become a critical option for patients seeking relief from debilitating seizures, clarifying precisely what is cannabidiol oral solution used for.